1. Phylogeny  
   RSKR, also known as SGK494 or Sugen kinase 494, is categorized as a member of the AGC kinase superfamily and is officially designated as the Ribosomal protein S6 kinase‐related protein, with gene symbol RSKR and UniProt identifier Q96LW2 (arencibia2013agcproteinkinases pages 1-2).  
   Phylogenetic analyses based on comprehensive kinase surveys have assigned RSKR to an evolutionarily conserved group that includes more than 60 kinases in the human genome, and it belongs to a cluster characterized by a conserved catalytic core, regulatory phosphorylation sites, and an allosteric PIF-pocket shared by members such as PDK1, AKT/PKB, PKC, SGK, and RSK (arencibia2013agcproteinkinases pages 1-2, jacinto2008torregulationof pages 6-7).  
   Comparative sequence studies employing structurally validated multiple sequence alignments have demonstrated that RSKR clusters tightly within the AGC kinase group, supporting its close evolutionary relationship with other serine/threonine kinases that trace their origins back to the Last Eukaryotic Common Ancestor (LECA) (modi2019astructurallyvalidated pages 22-26).  
   Moreover, RSKR is unique in that it is currently identified as the only member of its subfamily within the AGC kinase superfamily, indicating a divergent evolutionary trajectory relative to better‐characterized kinases such as classic RSK isoforms or SGK1 (arencibia2013agcproteinkinases pages 4-5, arencibia2013agcproteinkinases pages 5-6).  
   The evolutionary context of RSKR is further reinforced by its sequence homology with yeast kinases such as Ypk1 and Ypk2, which function as orthologs of SGK family constituents in lower eukaryotes, thereby underscoring the conservation of key regulatory domains across species (arencibia2013agcproteinkinases pages 5-6, jacinto2008torregulationof pages 9-10).  
   In addition, extensive phylogenetic mapping of the human kinome has confirmed that RSKR shares essential structural and catalytic features with other AGC kinases, including the presence of a conserved kinase domain architecture and residues critical for enzymatic activity (modi2019astructurallyvalidated pages 5-9, arencibia2013agcproteinkinases pages 2-3).  
   These results establish that RSKR occupies a distinct niche within the AGC kinase superfamily, reflecting both its evolutionary conservation and its divergence in terms of regulatory motifs when compared to its homologs (arencibia2013agcproteinkinases pages 3-4, thiriet2013preambletocytoplasmic pages 7-11).
2. Reaction Catalyzed  
   RSKR, as a prototypical serine/threonine kinase within the AGC superfamily, catalyzes protein phosphorylation by transferring the γ‐phosphate group from ATP to specific serine or threonine residues on substrate proteins, resulting in the formation of ADP, a phosphorylated protein, and the release of a proton (arencibia2013agcproteinkinases pages 2-3, jacinto2008torregulationof pages 6-7).  
   The generalized chemical reaction can be represented as follows: ATP + [protein]–(L‐serine or L‐threonine) → ADP + [protein]–(L‐serine/threonine)‐phosphate + H⁺, which is typical for AGC family kinases (arencibia2013agcproteinkinases pages 2-3).
3. Cofactor Requirements  
   RSKR requires the presence of Mg²⁺ ions as a crucial cofactor to stabilize the binding of ATP within its catalytic cleft, thereby facilitating efficient phosphate transfer during the phosphorylation reaction (arencibia2013agcproteinkinases pages 1-2, jacinto2008torregulationof pages 6-7).  
   The dependency on Mg²⁺ is consistent with the cofactor requirements observed for other members of the AGC kinase family, ensuring proper orientation of ATP for catalysis (arencibia2013agcproteinkinases pages 1-2).
4. Substrate Specificity  
   While the precise consensus substrate motif for RSKR has not been unambiguously defined, limited studies have highlighted that the kinase contains an activation segment motif, TICGT, with threonine 262 serving as a phosphorylation site; however, no clearly characterized substrate-recognition sequence has been reported (pearce2010thenutsand pages 1-2, arencibia2013agcproteinkinases pages 3-4).  
   In light of its classification as an AGC kinase, it is anticipated that RSKR phosphorylates serine/threonine residues within protein substrates; nevertheless, specific amino acid preferences or consensus sequences analogous to those observed for other AGC kinases remain to be fully elucidated (sakkiah2017overviewofthe pages 3-4).
5. Structure  
   RSKR exhibits the canonical bilobal fold characteristic of AGC kinases, comprising a small N-terminal lobe that predominantly binds ATP and a larger C-terminal lobe that accommodates substrate binding and catalysis, with the two lobes connected by a flexible hinge region (arencibia2013agcproteinkinases pages 1-2, modi2019astructurallyvalidated pages 5-9).  
   Within the catalytic domain, a conserved activation segment is present, which includes an activation loop containing the phosphorylation site at threonine 262 within the TICGT motif; this region is critical for the conformational changes required to achieve full enzymatic activity (pearce2010thenutsand pages 1-2).  
   Notably, RSKR lacks the typical hydrophobic and turn motifs that are commonly phosphorylated in other AGC kinases, a structural divergence that distinguishes it from its relatives and suggests that it has evolved a unique regulatory mechanism (arencibia2013agcproteinkinases pages 3-4, arencibia2013agcproteinkinases pages 4-5).  
   A particularly unique structural feature of RSKR is the presence of an endogenous cysteine residue at the gatekeeper position within its ATP-binding pocket, a rare attribute among human kinases that has been exploited in chemical genetic strategies to enable selective covalent inhibitor binding (garske2011chemicalgeneticstrategy pages 1-2, garske2011chemicalgeneticstrategy pages 6-7).  
   Additional conserved structural elements, such as the PIF-pocket, are also present in RSKR; this allosteric site, which in other AGC kinases facilitates interaction with regulatory partners and substrates during activation, is predicted from homology models to be structurally intact despite the limited experimental structural data available for this kinase (arencibia2013agcproteinkinases pages 8-9, modi2019astructurallyvalidated pages 26-29).  
   In the absence of high-resolution crystallographic data specific to RSKR, current structural insights are derived largely from comparative analysis and homology modeling using experimentally determined structures of other AGC family members, which supports the presence of the characteristic catalytic core and distinctive regulatory features observed in this kinase (modi2019astructurallyvalidated pages 5-9).
6. Regulation  
   Regulation of RSKR is primarily mediated by phosphorylation events that occur within its activation segment, where phosphorylation of threonine 262 is considered a pivotal step in switching the kinase into an active conformation (pearce2010thenutsand pages 1-2, arencibia2013agcproteinkinases pages 2-3).  
   Unlike many other AGC kinases, RSKR does not exhibit well-documented phosphorylation at the hydrophobic or turn motifs, a notable divergence that suggests a unique regulatory mechanism within its subfamily (arencibia2013agcproteinkinases pages 3-4, arencibia2013agcproteinkinases pages 5-6).  
   The PIF-pocket—a conserved structural motif within AGC kinases that facilitates substrate docking and modulates activation through allosteric interactions—is present in RSKR and is believed to contribute to its regulation by stabilizing the active conformation upon binding of regulatory elements (arencibia2013agcproteinkinases pages 8-9, jacinto2008torregulationof pages 6-7).  
   Moreover, the presence of an endogenous cysteine gatekeeper residue in RSKR introduces an additional layer of regulatory potential, as it allows for the possibility of covalent modification by electrophilic inhibitors, a strategy that has been successfully applied to a subset of human kinases with similar structural features (garske2011chemicalgeneticstrategy pages 7-7).  
   Although comprehensive characterization of the upstream kinases and phosphatases that modulate RSKR activity remains limited, its inclusion in the AGC kinase superfamily implies that regulatory enzymes such as PDK1 may be involved in phosphorylating its activation loop, thereby coordinating its activity within broader signaling networks (jacinto2008torregulationof pages 6-7, arencibia2013agcproteinkinases pages 2-3).
7. Function  
   RSKR functions as a serine/threonine protein kinase and, in accordance with its classification within the AGC kinase superfamily, is presumed to participate in intracellular signaling pathways that govern critical cellular processes such as growth, proliferation, survival, and metabolism (arencibia2013agcproteinkinases pages 1-2, jacinto2008torregulationof pages 9-10).  
   Despite its structural and regulatory characterization, the physiological role of RSKR remains largely uncharacterized, and its substrate repertoire and interacting partners have not yet been fully defined in the current literature (arencibia2013agcproteinkinases pages 4-5, garske2011chemicalgeneticstrategy pages 3-4).  
   Nonetheless, by virtue of its conserved catalytic core and regulatory phosphorylation mechanisms, RSKR is anticipated to modulate signaling cascades in a manner similar to other AGC kinases such as the p90 ribosomal S6 kinase (RSK) and serum/glucocorticoid-regulated kinase (SGK) families, both of which play roles in regulating protein synthesis, cell cycle progression, and stress responses (thiriet2013preambletocytoplasmic pages 7-11, jacinto2008torregulationof pages 9-10).  
   The evolutionary conservation of RSKR suggests that, although its specific functional outputs remain to be elucidated, it is likely to be involved in fundamental aspects of cellular regulation, with potential contributions to processes that require tight control of phosphorylation-dependent signaling (arencibia2013agcproteinkinases pages 2-3, modi2019astructurallyvalidated pages 22-26).  
   Current evidence does not establish tissue-specific expression patterns or defined roles in particular signaling pathways for RSKR, and further experimental work is needed to clarify whether it participates in common pathways such as those mediated by TOR, PDK1, or ERK MAPK cascades (jacinto2008torregulationof pages 9-10, arencibia2013agcproteinkinases pages 16-17).
8. Other Comments  
   RSKR, referred to interchangeably as SGK494 or Sugen kinase 494, remains a poorly characterized member of the AGC kinase family, and its orphan status highlights both a unique evolutionary trajectory and an opportunity for future investigation into novel regulatory mechanisms (arencibia2013agcproteinkinases pages 4-5, garske2011chemicalgeneticstrategy pages 1-2).  
   A notable and distinguishing feature of RSKR is its endogenous cysteine gatekeeper residue, which is present in only a small subset of human kinases and offers a strategic target for the development of covalent inhibitors; this feature has been exploited in chemical genetic studies to achieve high selectivity in kinase inhibition (garske2011chemicalgeneticstrategy pages 6-7, garske2011chemicalgeneticstrategy pages 7-7).  
   Despite extensive efforts in kinase profiling and inhibitor development for other members of the AGC superfamily, specific inhibitors targeting RSKR have not yet been reported, although the strategy of covalent modification via the cysteine gatekeeper presents a promising approach for the development of highly selective chemical probes (garske2011chemicalgeneticstrategy pages 3-4, pugh2014developingchemicalbiological pages 54-59).  
   Additionally, while many AGC kinases are known to be involved in a variety of pathological conditions including cancer, metabolic disorders, and neurological diseases, no direct disease associations have been definitively established for RSKR at this time, warranting further investigation to determine its potential role in human disease (arencibia2013agcproteinkinases pages 16-17, sakkiah2017overviewofthe pages 3-4).  
   The unique molecular features and regulatory potential of RSKR underscore its relevance as a subject of future functional and therapeutic studies, particularly as advances in chemical biology and structural modeling continue to refine our understanding of its kinase domain architecture and regulatory interactions (modi2019astructurallyvalidatedmultiple pages 12-12, arencibia2013agcproteinkinases pages 5-6).

References

1. (arencibia2013agcproteinkinases pages 1-2): José M. Arencibia, Daniel Pastor-Flores, Angelika F. Bauer, Jörg O. Schulze, and Ricardo M. Biondi. Agc protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1834:1302-1321, Jul 2013. URL: https://doi.org/10.1016/j.bbapap.2013.03.010, doi:10.1016/j.bbapap.2013.03.010. This article has 238 citations.
2. (arencibia2013agcproteinkinases pages 3-4): José M. Arencibia, Daniel Pastor-Flores, Angelika F. Bauer, Jörg O. Schulze, and Ricardo M. Biondi. Agc protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1834:1302-1321, Jul 2013. URL: https://doi.org/10.1016/j.bbapap.2013.03.010, doi:10.1016/j.bbapap.2013.03.010. This article has 238 citations.
3. (jacinto2008torregulationof pages 6-7): Estela Jacinto and Anja Lorberg. Tor regulation of agc kinases in yeast and mammals. Biochemical Journal, 410:19-37, Jan 2008. URL: https://doi.org/10.1042/bj20071518, doi:10.1042/bj20071518. This article has 265 citations and is from a domain leading peer-reviewed journal.
4. (thiriet2013preambletocytoplasmic pages 7-11): M Thiriet M Thiriet. Preamble to cytoplasmic protein kinases. Biomathematical and Biomechanical Modeling of the Circulatory and Ventilatory Systems, pages 109-135, Jul 2013. URL: https://doi.org/10.1007/978-1-4614-4370-4\_3, doi:10.1007/978-1-4614-4370-4\_3. This article has 2 citations.
5. (arencibia2013agcproteinkinases pages 2-3): José M. Arencibia, Daniel Pastor-Flores, Angelika F. Bauer, Jörg O. Schulze, and Ricardo M. Biondi. Agc protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1834:1302-1321, Jul 2013. URL: https://doi.org/10.1016/j.bbapap.2013.03.010, doi:10.1016/j.bbapap.2013.03.010. This article has 238 citations.
6. (arencibia2013agcproteinkinases pages 4-5): José M. Arencibia, Daniel Pastor-Flores, Angelika F. Bauer, Jörg O. Schulze, and Ricardo M. Biondi. Agc protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1834:1302-1321, Jul 2013. URL: https://doi.org/10.1016/j.bbapap.2013.03.010, doi:10.1016/j.bbapap.2013.03.010. This article has 238 citations.
7. (arencibia2013agcproteinkinases pages 5-6): José M. Arencibia, Daniel Pastor-Flores, Angelika F. Bauer, Jörg O. Schulze, and Ricardo M. Biondi. Agc protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1834:1302-1321, Jul 2013. URL: https://doi.org/10.1016/j.bbapap.2013.03.010, doi:10.1016/j.bbapap.2013.03.010. This article has 238 citations.
8. (arencibia2013agcproteinkinases pages 8-9): José M. Arencibia, Daniel Pastor-Flores, Angelika F. Bauer, Jörg O. Schulze, and Ricardo M. Biondi. Agc protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1834:1302-1321, Jul 2013. URL: https://doi.org/10.1016/j.bbapap.2013.03.010, doi:10.1016/j.bbapap.2013.03.010. This article has 238 citations.
9. (garske2011chemicalgeneticstrategy pages 1-2): Adam L. Garske, Ulf Peters, Arianna T. Cortesi, Jenny L. Perez, and Kevan M. Shokat. Chemical genetic strategy for targeting protein kinases based on covalent complementarity. Proceedings of the National Academy of Sciences, 108:15046-15052, Aug 2011. URL: https://doi.org/10.1073/pnas.1111239108, doi:10.1073/pnas.1111239108. This article has 120 citations.
10. (jacinto2008torregulationof pages 9-10): Estela Jacinto and Anja Lorberg. Tor regulation of agc kinases in yeast and mammals. Biochemical Journal, 410:19-37, Jan 2008. URL: https://doi.org/10.1042/bj20071518, doi:10.1042/bj20071518. This article has 265 citations and is from a domain leading peer-reviewed journal.
11. (modi2019astructurallyvalidated pages 22-26): Vivek Modi and Roland L. Dunbrack. A structurally validated sequence alignment of all 497 typical human protein kinase domains. bioRxiv, Sep 2019. URL: https://doi.org/10.1101/776740, doi:10.1101/776740. This article has 8 citations.
12. (modi2019astructurallyvalidated pages 5-9): Vivek Modi and Roland L. Dunbrack. A structurally validated sequence alignment of all 497 typical human protein kinase domains. bioRxiv, Sep 2019. URL: https://doi.org/10.1101/776740, doi:10.1101/776740. This article has 8 citations.
13. (pearce2010thenutsand pages 1-2): Laura R. Pearce, David Komander, and Dario R. Alessi. The nuts and bolts of agc protein kinases. Nature Reviews Molecular Cell Biology, 11:9-22, Jan 2010. URL: https://doi.org/10.1038/nrm2822, doi:10.1038/nrm2822. This article has 1655 citations and is from a domain leading peer-reviewed journal.
14. (pugh2014developingchemicalbiological pages 54-59): KM Pugh. Developing chemical biological tools to probe phosphorylation in p. falciparum. Unknown journal, 2014.
15. (sakkiah2017overviewofthe pages 3-4): Sugunadevi Sakkiah, Guang Ping Cao, Staya P. Gupta, and Keun Woo Lee. Overview of the structure and function of protein kinases. Current Enzyme Inhibition, 13:81-88, Jul 2017. URL: https://doi.org/10.2174/1573408013666161226155608, doi:10.2174/1573408013666161226155608. This article has 13 citations and is from a peer-reviewed journal.
16. (garske2011chemicalgeneticstrategy pages 6-7): Adam L. Garske, Ulf Peters, Arianna T. Cortesi, Jenny L. Perez, and Kevan M. Shokat. Chemical genetic strategy for targeting protein kinases based on covalent complementarity. Proceedings of the National Academy of Sciences, 108:15046-15052, Aug 2011. URL: https://doi.org/10.1073/pnas.1111239108, doi:10.1073/pnas.1111239108. This article has 120 citations.
17. (garske2011chemicalgeneticstrategy pages 7-7): Adam L. Garske, Ulf Peters, Arianna T. Cortesi, Jenny L. Perez, and Kevan M. Shokat. Chemical genetic strategy for targeting protein kinases based on covalent complementarity. Proceedings of the National Academy of Sciences, 108:15046-15052, Aug 2011. URL: https://doi.org/10.1073/pnas.1111239108, doi:10.1073/pnas.1111239108. This article has 120 citations.
18. (modi2019astructurallyvalidated pages 26-29): Vivek Modi and Roland L. Dunbrack. A structurally validated sequence alignment of all 497 typical human protein kinase domains. bioRxiv, Sep 2019. URL: https://doi.org/10.1101/776740, doi:10.1101/776740. This article has 8 citations.
19. (modi2019astructurallyvalidatedmultiple pages 12-12): Vivek Modi and Roland L. Dunbrack. A structurally-validated multiple sequence alignment of 497 human protein kinase domains. Scientific Reports, Dec 2019. URL: https://doi.org/10.1038/s41598-019-56499-4, doi:10.1038/s41598-019-56499-4. This article has 118 citations and is from a poor quality or predatory journal.
20. (arencibia2013agcproteinkinases pages 16-17): José M. Arencibia, Daniel Pastor-Flores, Angelika F. Bauer, Jörg O. Schulze, and Ricardo M. Biondi. Agc protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1834:1302-1321, Jul 2013. URL: https://doi.org/10.1016/j.bbapap.2013.03.010, doi:10.1016/j.bbapap.2013.03.010. This article has 238 citations.
21. (garske2011chemicalgeneticstrategy pages 3-4): Adam L. Garske, Ulf Peters, Arianna T. Cortesi, Jenny L. Perez, and Kevan M. Shokat. Chemical genetic strategy for targeting protein kinases based on covalent complementarity. Proceedings of the National Academy of Sciences, 108:15046-15052, Aug 2011. URL: https://doi.org/10.1073/pnas.1111239108, doi:10.1073/pnas.1111239108. This article has 120 citations.